Patents by Inventor Ted C. K. Lee
Ted C. K. Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7906299Abstract: A prothrombin time reagent for determination of low molecular weight heparin in fresh whole blood and in anti-coagulant treated blood is provided. The reagent is composed of recombinant animal tissue factor, and a mixture of synthetic phospholipids, which mixture includes a phosphatidylalcohol. A formulation buffer which includes a sensitivity adjuster is used in formulating the reagent. The recombinant animal tissue factor includes rabbit brain. The synthetic phospholipids of the mixture include palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylserine (POPS), and a phosphatidylalcohol. The phosphatidyl alcohol includes dioleoylphosphatidylethanol, dioleoylphosphatidylmethanol, dioleoylphosphatidylpropanol, dioleoylphosphatidylbutanol, and dioleoylphosphatidylinositol. The sensitivity adjuster included in the formulation buffer is ?-Cyclodextrin. The formulated reagent is air-dried and remains stable for at least 3 weeks at 37° C.Type: GrantFiled: April 15, 2008Date of Patent: March 15, 2011Assignee: International Technidyne CorporationInventors: Ted C. K. Lee, Amanda B. McBride, Frank M. LaDuca
-
Publication number: 20090053754Abstract: A prothrombin time reagent for determination of low molecular weight heparin in fresh whole blood and in anti-coagulant treated blood is provided. The reagent is composed of recombinant animal tissue factor, and a mixture of synthetic phospholipids, which mixture includes a phosphatidylalcohol. A formulation buffer which includes a sensitivity adjuster is used in formulating the reagent. The recombinant animal tissue factor includes rabbit brain. The synthetic phospholipids of the mixture include palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylserine (POPS), and a phosphatidylalcohol. The phosphatidyl alcohol includes dioleoylphosphatidylethanol, dioleoylphosphatidylmethanol, dioleoylphosphatidylpropanol, dioleoylphosphatidylbutanol, and dioleoylphosphatidylinositol. The sensitivity adjuster included in the formulation buffer is ?-Cyclodextrin. The formulated reagent is air-dried and remains stable for at least 3 weeks at 37° C.Type: ApplicationFiled: April 15, 2008Publication date: February 26, 2009Applicant: International Technidyne CorporationInventors: Ted C. K. Lee, Amanda B. McBride, Frank M. LaDuca
-
Patent number: 7358337Abstract: A prothrombin time reagent for determination of low molecular weight heparin in frsh whole blood and in anti-coagulant treated blood is provided. The reagent is composed of recombinant animal tissue factor, and a mixture of synthetic phospholipids, which mixture includes a phosphatidylalcohol. A formulation buffer which includes a sensitivity adjuster is used in formulating the reagent. The recombinant animal tissue factor includes rabbit brain. The synthetic phospholipids of the mixture include palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylserine (POPS), and a phosphatidylalcohol. The phosphatidyl alcohol includes dioleoylphosphatidylethanol, dioleoylphosphatidylmethanol, dioleoylphosphatidylpropanol, dioleoylphosphatidylbutanol, and dioleoylphosphatidylinositol. The sensitivity adjuster included in the formulation buffer is ?-Cyclodextrin. The formulated reagent is air-dried and remains stable for at least 3 weeks at 37° C.Type: GrantFiled: August 16, 2002Date of Patent: April 15, 2008Assignee: International Technidyne CorporationInventors: Ted C. K. Lee, Amanda B. McBride, Frank M. LaDuca
-
Patent number: 6733985Abstract: A reagent for determining prothrombin time (PT) including a recombinant protein tissue factor, a mixture of synthetic phospholipids, and a beta, gamma, or delta amino acid stabilizing compound is described for monitoring extrinsic blood coagulation activities. The source for the recombinant protein tissue factor is rabbit brain, and the phospholipids employed are palmitoyloleoylphosphatidylcholine (POPC) and palmitoyloleoylphosphatidylserine (POPS). The particular formulation buffer used to dilute the lipidated tissue factor provides a reagent that is optionally dried without lyophilization and remains stable for at least about 2 weeks at 37 C as either a liquid or a dried powder. A method for preparing the improved PT reagent and a method of using the reagent to analyze blood PT is also provided.Type: GrantFiled: May 19, 1999Date of Patent: May 11, 2004Assignee: International Technidyne CorporationInventor: Ted C. K. Lee
-
Publication number: 20040033551Abstract: A prothrombin time reagent for determination of low molecular weight heparin in fresh whole blood and in anti-coagulant treated blood is provided. The reagent is composed of recombinant animal tissue factor, and a mixture of synthetic phospholipids, which mixture includes a phosphatidylalcohol. A formulation buffer which includes a sensitivity adjuster is used in formulating the reagent. The recombinant animal tissue factor includes rabbit brain. The synthetic phospholipids of the mixture include palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylserine (POPS), and a phosphatidylalcohol. The phosphatidyl alcohol includes dioleoylphosphatidylethanol, dioleoylphosphatidylmethanol, dioleoylphosphatidylpropanol, dioleoylphosphatidylbutanol, and dioleoylphosphatidylinositol. The sensitivity adjuster included in the formulation buffer is &ggr;-Cyclodextrin. The formulated reagent is air-dried and remains stable for at least 3 weeks at 37° C.Type: ApplicationFiled: August 16, 2002Publication date: February 19, 2004Inventors: Ted C. K. Lee, Amanda B. McBride, Frank M. LaDuca
-
Patent number: 6183979Abstract: A method for preparation of an air-dried prothrombin time (PT) reagent which uses a recombinant protein and synthetic phospholipids is described. The source for the recombinant protein is rabbit brain, and the phospholipids employed are palmitoyloleoylphosphatidylcholine (POPC) and palmitoyloleoylphosphatidylserine (POPS). The particular formulation buffer used to dilute the lipidated tissue factor provides a reagent that is dried without lyophilization and remains stable for at least 2 weeks at 37 C. A method for preparing the improved PT reagent and a method of using the reagent to analyze blood PT is also provided.Type: GrantFiled: March 24, 1999Date of Patent: February 6, 2001Assignee: International Technidyne CorporationInventors: Ted C. K. Lee, Paul Michael D'Agostino, Anne Jessica Gorman
-
Patent number: 5847086Abstract: Processes for preparing aqueous solutions of cysteine-altered von Willebrand Factor fragment which are substantially free of aggregate and capable of therapeutic use for treating thrombosis are provided. The claimed process comprises providing an aqueous solution of vWF fragment and denaturant and containing undesired contaminants, said solution having an acidic pH; separating said contaminants from said solution by contacting said solution with an affinity chromatography medium to which said vWF fragments adhere; eluting said vWF fragment from said affinity chromatography medium in the presence of the denaturant; and separating the eluted fragment from said denaturant while maintaining the aqueous solution of the fragment at a pH of about 2.5 to less than about 5.5 to increase monomerization of, and decrease aggregation of, said fragment, thereby forming an aqueous solution of vWF fragment which is substantially free of aggregate.Type: GrantFiled: June 7, 1995Date of Patent: December 8, 1998Assignee: Centeon L.L.C.Inventors: David L. Farb, Michael E. Hrinda, Ted C. K. Lee, Christopher P. Prior, David Weber
-
Patent number: 5605884Abstract: Stable, highly purified Factor VIII protein formulations are provided in high ionic strength media which comprises: sodium chloride, potassium chloride or mixtures thereof; calcium chloride; and histidine as the buffering agent.Type: GrantFiled: December 27, 1994Date of Patent: February 25, 1997Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.Inventors: Ted C. K. Lee, Michael E. Hrinda
-
Patent number: 5550028Abstract: The compound 2,3,5,6-tetrahydroxy-1,4-quinone, its derivatives and structural analogs are used as activators for intrinsic blood coagulation and as diagnostic reagents for the activated partial thromboplastin time test of blood coagulation.Type: GrantFiled: June 7, 1995Date of Patent: August 27, 1996Assignee: Dade International Inc.Inventors: Ted C. K. Lee, Franz H. Pelzer, Leslie A. Motley
-
Patent number: 5539086Abstract: An aqueous solution of cysteine-altered von Willebrand Factor fragment which is substantially free of aggregate and capable of therapeutic use for treating thrombosis and a process for preparing such a solution comprising:(A) providing an aqueous solution of the fragment and denaturant;(B) purifying the solution of fragment and denaturant under conditions which promote conversion of aggregated forms of the fragment to the dimeric and/or monomeric forms thereof to provide purified fragment;(C) separating the dissolved, purified fragment from the denaturant while maintaining the aqueous solution of the fragment at a pH of about 2.5 to less than about 5.5 to increase monomerization of, and decrease aggregation of, said purified fragment, thereby forming an aqueous solution of fragment which is substantially free of aggregate.Type: GrantFiled: February 18, 1994Date of Patent: July 23, 1996Assignee: Rh one-Poulenc Rorer Pharmaceuticals Inc.Inventors: David L. Farb, Michael E. Hrinda, Ted C. K. Lee, Christopher P. Prior
-
Patent number: 4977246Abstract: Disclosed is a method of recovery of antihemophilic factor (AHF) from human plasma by precipitation with citric acid, sodium citrate, or potassium citrate.Type: GrantFiled: June 6, 1989Date of Patent: December 11, 1990Assignee: Rorer Pharmaceutical CorporationInventors: Ted C. K. Lee, Michael E. Hrinda
-
Patent number: 4877608Abstract: Stable factor VIII and other plasma protein formulations are provided in low ionic strength media which comprises: sodium chloride, potassium chloride or mixtures thereof; lysine hydrochloride; and histidine as the buffering agent.Type: GrantFiled: November 9, 1987Date of Patent: October 31, 1989Assignee: Rorer Pharmaceutical CorporationInventors: Ted C. K. Lee, Michael E. Hrinda